FDA’s Revised Hep C Drug Development Guidelines May Have Short Lifespan
Executive Summary
Recently released draft guidance reduces the time to primary efficacy endpoint assessment and provides specific trial design recommendations for interferon-free regimens. However, FDA includes plenty of caveats warning that recommendations will evolve with imminent changes in the therapeutic area.